# Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a company headquartered in Boston, MA, United States.

## Company overview

- **Legal name:** Paratek Pharmaceuticals, Inc.
- **Former names in filing history:** Transcept Pharmaceuticals Inc (2008-10-31 to 2014-10-30); NOVACEA INC (2002-07-23 to 2009-01-20)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Boston, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001178711

## About

Paratek Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001178711, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-03-16, it reported annual revenue of USD 160,268,000; net income of USD -63,566,000; total assets of USD 172,538,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $160.3M (USD 160,268,000)
- **Net income:** -$63.6M (USD -63,566,000)
- **Total assets:** $172.5M (USD 172,538,000)
- **Cash and equivalents:** $34.2M (USD 34,248,000)
- **Operating cash flow:** -$66.1M (USD -66,141,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $130.2M (USD 130,162,000)
- **Net income:** -$59.1M (USD -59,084,000)
- **Total assets:** $183.9M (USD 183,869,000)
- **Cash and equivalents:** $80.4M (USD 80,367,000)
- **Operating cash flow:** -$48.3M (USD -48,273,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $46.9M (USD 46,924,000)
- **Net income:** -$96.5M (USD -96,541,000)
- **Total assets:** $176.9M (USD 176,853,000)
- **Cash and equivalents:** $105.2M (USD 105,157,000)
- **Operating cash flow:** -$103.4M (USD -103,424,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $16.5M (USD 16,544,000)
- **Net income:** -$128.8M (USD -128,790,000)
- **Total assets:** $251.1M (USD 251,079,000)
- **Cash and equivalents:** $102.3M (USD 102,302,000)
- **Operating cash flow:** -$134.0M (USD -134,045,000)

## Recent SEC filings

- Form 8-K — filed 2023-09-21 — period 2023-09-21 — 8-K
- Form 8-K — filed 2023-09-18 — period 2023-09-18 — 8-K
- Form 8-K — filed 2023-09-11 — period 2023-09-11 — 8-K
- Form SC 13G — filed 2023-09-05 — THE SCHEDULE 13G
- Form 10-Q — filed 2023-08-03 — period 2023-06-30 — 10-Q
- Form 8-K — filed 2023-07-11 — period 2023-07-06 — 8-K
- Form 8-K — filed 2023-06-07 — period 2023-06-06 — 8-K
- Form DEF 14A — filed 2023-05-26 — DEFINITIVE PROXY STATEMENT
- Form 10-Q — filed 2023-05-09 — period 2023-03-31 — 10-Q
- Form 10-K/A — filed 2023-04-27 — period 2022-12-31 — 10-K/A
- Form SC 13D — filed 2023-03-30 — SCHEDULE 13D
- Form 10-K — filed 2023-03-16 — period 2022-12-31 — 10-K

---

Updated: 2026-10-23T20:10:52Z

Canonical page: https://altss.com/profile/paratek-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology